SLC5A2 and heart failure: Both DAPA-HF and EMPEROR-Reduced trials showed that in patients with heart failure, SGLT2 inhibitor reduced the combined risk of cardiovascular death or hospitalization for heart failure [10, 11], and consistent with the above clinical trials, several studies indicated that the benefits of SGLT-2 inhibitors depending on its anti-inflammatory effects [12–14].